Featured Research

from universities, journals, and other organizations

Variation Of Normal Protein Could Be Key To Resistance To Common Cancer Drug

Date:
August 29, 2008
Source:
University of California - San Diego
Summary:
Researchers have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.

Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.

Related Articles


The scientists say that such findings, reported online this week in the journal Proceedings of the National Academy of Sciences, are important to understanding how personalized therapies may be developed for patients.

In a series of experiments, Jean Wang, Ph.D., distinguished professor of medicine and Associate Director of Basic Research at the Moores UCSD Cancer Center, Richard Kolodner, Ph.D., professor of medicine at UC San Diego and Executive Director, Laboratory Science and Technology at the Ludwig Institute for Cancer Research and their co-workers found evidence that when a specific variant form of a so-called "mismatch repair" protein, PMS2, is active, cisplatin doesn't kill cancer cells the way it normally does. The cancer is, in effect, resistant to the drug.

As a repair protein, PMS2 is crucial to fixing mistakes in DNA that may occur during replication. It also has a darker side, playing a role in instructing cells to kill themselves.

For example, Wang, Kolodner and their colleagues had previously shown that PMS2 is needed for cisplatin to kill cancer cells, activating another protein, p73, which in turn begins a cascade of steps leading to cell suicide. Since most cancer cell-killing therapies such as chemotherapy and radiation take advantage of this process, the team wanted to better understand how cancer cells might evade such suicide instructions, rendering the therapy ineffective.

Defects in such mismatch repair genes and proteins can increase cancer risk, particularly for hereditary colon cancer. The researchers knew that the PMS2 gene had at least 12 different forms in humans. In studies on mouse cells lacking PMS2, they tested several different variations of the human PMS2 protein, for the most part showing that PMS2 indeed sensitized cells to cisplatin, causing cell suicide. They finally found that one variant, PMS2 (R20Q), failed to activate p73 and bring about cell death in response to cisplatin. The drug's toxic effects were compromised in cells with the PMS2 (R20Q).

Wang sees many possibilities for future research. "We don't know how many people have this PMS2 variant," she explained, noting that cisplatin is the first-line therapy for testicular and ovarian cancers. "We would like to take these findings to human tumor samples. If we could find out which individuals carry this variant, it might change our decisions about treating them with cisplatin."

If researchers could track how fast ovarian cancer patients' tumors develop resistance to cisplatin, she said, correlation studies might be performed to find risk factors, such as gene variants.

Ideally, scientists will ultimately design new drugs that can push cancer cells into cell suicide, rather than repairing themselves, she noted.

Other authors include Irina Hunton and Atsuko Yoshioka-Yamashita, Ph.D,. UC San Diego, Winfried Edelmann, Ph.D., and Elena Avdievich, Ph.D., Albert Einstein College of Medicine, Ivana Marinovic-Terzic, M.D., University of Split, Croatia, and Hideki Shimodaira, Ph.D., Tohoko University, Japan.

The work received funding support from the National Institute for Environmental Health Sciences, the National Cancer Institute and the Japan Society for the Promotion of Science Research Fellowships for Young Scientists.


Story Source:

The above story is based on materials provided by University of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Diego. "Variation Of Normal Protein Could Be Key To Resistance To Common Cancer Drug." ScienceDaily. ScienceDaily, 29 August 2008. <www.sciencedaily.com/releases/2008/08/080828093351.htm>.
University of California - San Diego. (2008, August 29). Variation Of Normal Protein Could Be Key To Resistance To Common Cancer Drug. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2008/08/080828093351.htm
University of California - San Diego. "Variation Of Normal Protein Could Be Key To Resistance To Common Cancer Drug." ScienceDaily. www.sciencedaily.com/releases/2008/08/080828093351.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins